

VICURON PHARMACEUTICALS INC  
Form 8-K  
December 22, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):**

**December 21, 2004**

---

**Vicuron Pharmaceuticals Inc.**

**(Exact Name of Registrant As Specified in its Charter)**

---

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-31145**  
**(Commission File Number)**

**04-3278032**  
**I.R.S. Employer**  
  
**Identification Number)**

**455 South Gulph Road, Suite 305, King of Prussia, PA 19406**

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On December 21, 2004, Vicuron Pharmaceuticals Inc. (the Company ) issued a press release announcing that the Company has submitted a New Drug Application ( NDA ) to the U.S. Food and Drug Administration ( FDA ) for dalbavancin, a novel antibiotic for the treatment of complicated skin and soft tissue infections. A copy of the press release is included as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(c) Exhibits**

99.1 Press Release of Vicuron Pharmaceuticals Inc. dated December 21, 2004, reporting its submission of an NDA to the FDA for dalbavancin.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.

(Registrant)

Date: December 22, 2004

By: /s/ George F. Horner

---

George F. Horner III  
President and Chief Executive Officer

**INDEX TO EXHIBITS**

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1               | Press release of Vicuron Pharmaceuticals Inc. dated December 21, 2004, reporting its submission of an NDA to the FDA for dalbavancin. |